BioAge Labs (NASDAQ:BIOA) Stock Dropped to Strong Sell by Wall Street Zen

Wall Street Zen cut shares of BioAge Labs (NASDAQ:BIOA) from a sell rating to a strong sell rating in a report issued on Saturday,Wall Street Zen reports.

BIOA has been the topic of several other research reports. Needham & Company LLC cut their price target on BioAge Labs from $50.00 to $35.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. Jefferies Financial Group set a $21.00 price objective on BioAge Labs in a research note on Friday, July 31st. Weiss Ratings downgraded BioAge Labs from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday. Roth Capital reissued a “buy” rating and issued a $25.00 target price on shares of BioAge Labs in a research note on Wednesday, September 9th. Finally, BTIG Research restated a “buy” rating and set a $40.00 price target on shares of BioAge Labs in a report on Tuesday, September 8th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $36.57.

BioAge Labs Price Performance

NASDAQ:BIOA opened at $6.34 on Friday. The firm has a market capitalization of $291.01 million, a P/E ratio of -2.66 and a beta of 1.08. BioAge Labs has a one year low of $5.04 and a one year high of $25.95. The company’s 50-day simple moving average is $8.96 and its 200 day simple moving average is $15.56.

BioAge Labs (NASDAQ:BIOA) last announced its earnings results on Wednesday, August 5th. The company reported ($0.58) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.07. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%. The business had revenue of $2.45 million during the quarter. On average, equities research analysts expect that BioAge Labs will post -2.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of BIOA. Dimensional Fund Advisors LP bought a new stake in shares of BioAge Labs in the first quarter worth approximately $3,746,000. Renaissance Technologies LLC raised its holdings in shares of BioAge Labs by 653.2% during the first quarter. Renaissance Technologies LLC now owns 138,588 shares of the company’s stock valued at $2,424,000 after purchasing an additional 120,188 shares during the last quarter. Stempoint Capital LP bought a new position in BioAge Labs during the first quarter valued at approximately $5,923,000. Walleye Capital LLC bought a new position in BioAge Labs during the second quarter valued at approximately $8,686,000. Finally, Janus Henderson Group PLC boosted its holdings in BioAge Labs by 411.8% in the first quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock worth $36,597,000 after purchasing an additional 1,685,063 shares during the last quarter.

About BioAge Labs

BioAge Labs, Inc is a clinical-stage biotechnology company focused on developing medicines for diseases associated with aging. The company uses human longevity data, machine learning and biology research to identify therapeutic targets and develop treatments intended to address the biological drivers of aging and age-related decline.

BioAge’s pipeline has included azelaprag, formerly known as BGE-105, an investigational small-molecule agonist of the apelin receptor. The company has evaluated azelaprag in clinical studies involving muscle function and has also investigated its potential use in combination with incretin-based medicines for obesity.